AU2018283957B2 - ZIKA virus strains for treatment of glioblastoma - Google Patents

ZIKA virus strains for treatment of glioblastoma Download PDF

Info

Publication number
AU2018283957B2
AU2018283957B2 AU2018283957A AU2018283957A AU2018283957B2 AU 2018283957 B2 AU2018283957 B2 AU 2018283957B2 AU 2018283957 A AU2018283957 A AU 2018283957A AU 2018283957 A AU2018283957 A AU 2018283957A AU 2018283957 B2 AU2018283957 B2 AU 2018283957B2
Authority
AU
Australia
Prior art keywords
zikv
protein
mutation
amino acid
engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018283957A
Other languages
English (en)
Other versions
AU2018283957A1 (en
Inventor
Milan CHHEDA
Michael Diamond
Matthew Gorman
Jeremy RICH
Pei-Yong Shi
Zhe ZHU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
University of Texas Medical Branch at Galveston
Lerner Research Institute Cleveland Clinic
Original Assignee
Washington University in St Louis WUSTL
University of Texas Medical Branch at Galveston
Lerner Research Institute Cleveland Clinic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL, University of Texas Medical Branch at Galveston, Lerner Research Institute Cleveland Clinic filed Critical Washington University in St Louis WUSTL
Publication of AU2018283957A1 publication Critical patent/AU2018283957A1/en
Application granted granted Critical
Publication of AU2018283957B2 publication Critical patent/AU2018283957B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/12—Animals modified by administration of exogenous cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018283957A 2017-06-12 2018-06-11 ZIKA virus strains for treatment of glioblastoma Active AU2018283957B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762518300P 2017-06-12 2017-06-12
US62/518,300 2017-06-12
US201762574537P 2017-10-19 2017-10-19
US62/574,537 2017-10-19
PCT/US2018/036858 WO2018231690A1 (en) 2017-06-12 2018-06-11 Zika virus strains for treatment of glioblastoma

Publications (2)

Publication Number Publication Date
AU2018283957A1 AU2018283957A1 (en) 2020-01-02
AU2018283957B2 true AU2018283957B2 (en) 2024-01-25

Family

ID=64660846

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018283957A Active AU2018283957B2 (en) 2017-06-12 2018-06-11 ZIKA virus strains for treatment of glioblastoma

Country Status (6)

Country Link
US (1) US12274725B2 (enExample)
EP (1) EP3638304B1 (enExample)
JP (1) JP7525853B2 (enExample)
AU (1) AU2018283957B2 (enExample)
CA (1) CA3067164A1 (enExample)
WO (1) WO2018231690A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3067164A1 (en) 2017-06-12 2018-12-20 Washington University Zika virus strains for treatment of glioblastoma
US10993975B2 (en) 2017-08-07 2021-05-04 The Nemours Foundation Zika virus treatment of CD24-positive tumors and diseases associated with abnormal T cell activation and treating or preventing Zika virus infections
US12473570B2 (en) 2019-05-21 2025-11-18 The Regents Of The University Of California Zika virus constructs and therapeutic compositions thereof
CN113679744B (zh) * 2020-05-18 2023-12-29 中国人民解放军军事科学院军事医学研究院 寨卡病毒或其与用于免疫检查点治疗的药物在治疗胶质母细胞瘤中的用途
JP7846133B2 (ja) * 2021-05-04 2026-04-14 アリヴィッド エルエルシー 脳腫瘍治療のための生物学的実体物
CN119137275A (zh) * 2022-02-22 2024-12-13 维罗生物公司 溶瘤病毒和使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170014502A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
US4241046A (en) 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4925661A (en) 1984-04-19 1990-05-15 Leaf Huang Target-specific cytotoxic liposomes
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US4755388A (en) 1984-11-09 1988-07-05 The Regents Of The University Of California Liposome-encapsulated 5-fluoropyrimidines and methods for their use
DE3542773A1 (de) 1985-12-04 1987-06-11 Roehm Pharma Gmbh Hautwirksame pharmaka mit liposomen als wirkstofftraeger
US4828837A (en) 1987-03-30 1989-05-09 Liposome Technology, Inc. Non-crystalline minoxidil composition, its production and application
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
US5043164A (en) 1989-01-17 1991-08-27 The University Of Tennessee Research Corporation Blood-stable, cholesterol-free liposomes
US5064655A (en) 1989-02-24 1991-11-12 Liposome Technology, Inc. Liposome gel composition and method
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
EP1861491A4 (en) 2005-02-16 2009-07-08 Replikun Biotech Pty Ltd FLAVIVIRUS REPLICON CONSTRUCTS FOR ANTITUMOR THERAPY
JP5779352B2 (ja) * 2008-03-14 2015-09-16 サノフィ パスツール バイオロジクス リミテッド ライアビリティ カンパニー 複製欠損フラビウイルスワクチンおよびワクチンベクター
WO2017004567A1 (en) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
US20190202886A1 (en) * 2016-05-11 2019-07-04 Ohio State Innovation Foundation ONCOLYTIC VIRUSES COMPRISING esRAGE AND METHODS OF TREATING CANCER
US10786537B2 (en) 2016-08-18 2020-09-29 Cedars-Sinai Medical Center Method of inducing an oncolytic effect on tumor cells using Zika virus
CA3067164A1 (en) 2017-06-12 2018-12-20 Washington University Zika virus strains for treatment of glioblastoma
US12178869B2 (en) 2017-12-22 2024-12-31 Codagenix Inc. Recombinant virus with codon-pair deoptimized region and uses thereof for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170014502A1 (en) * 2015-07-16 2017-01-19 Bharat Biotech International Limited Vaccine compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHAO SHAN ET AL: NATURE MEDICINE, vol. 23, no. 6, 10 April 2017 (2017-04-10), New York, pages 763 - 767, XP055539486, ISSN: 1078-8956, DOI: 10.1038/nm.4322 *
SHAN CHAO ET AL: CELL HOST & MICROBE, ELSEVIER, NL, vol. 19, no. 6, 16 May 2016 (2016-05-16), pages 891 - 900, XP029594479, ISSN: 1931-3128, DOI: 10.1016/J.CHOM.2016.05.004 *

Also Published As

Publication number Publication date
JP2020529395A (ja) 2020-10-08
CA3067164A1 (en) 2018-12-20
US20210145907A1 (en) 2021-05-20
US12274725B2 (en) 2025-04-15
WO2018231690A1 (en) 2018-12-20
EP3638304B1 (en) 2024-07-31
EP3638304A4 (en) 2021-02-24
JP7525853B2 (ja) 2024-07-31
EP3638304A1 (en) 2020-04-22
AU2018283957A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
EP3638304B1 (en) Engineered oncolytic zika virus for use in the treatment of cancer
JP6457003B2 (ja) 腫瘍溶解性ワクシニアウイルスの投与による腫瘍抗原に対する抗体の生成および腫瘍特異的補体依存性細胞傷害の生成
US9539307B2 (en) Compositions and methods for treating amyotrophic lateral sclerosis
JP2013213058A (ja) ウイルスを用いた新生物の処置
JP2003530301A (ja) ウイルスを用いた新生物の処置
KR101585702B1 (ko) 종양파괴 바이러스 요법에 대한 과다증식성 세포의 종양 억제인자-기초된 민감성
US20220088096A1 (en) Oncolytic myxoma virus expressing fast p14 to treat hematological cancer
de Oliveira et al. The small molecule AZD6244 inhibits dengue virus replication in vitro and protects against lethal challenge in a mouse model: LC de Oliveira et al.
Danthi et al. Bid regulates the pathogenesis of neurotropic reovirus
WO2019043282A1 (es) Producto de combinación que comprende una célula madre mesenquimal modificada y una sustancia antigénica
EP2904009B1 (en) Compounds for treating the remyelination blockade in diseases associated with the expression of herv-w envelope protein
WO2012118599A1 (en) C-abl tyrosine kinase inhibitors useful for inhibiting filovirus replication
US20240091285A1 (en) Compositions and methods of treatment of tumors expressing putative zika virus receptor proteins
BR112015017692A2 (pt) Vírus do sarampo infeccioso, mv-deltac infeccioso, método para preparar células, pdcs vacinais, composição farmacêutica e agrupamento de ingredientes ativos
Roebke Regulation of Cell Death by Reovirus Outer Capsid Proteins
US20240041959A1 (en) Novel modified reovirus and use thereof
Pruijssers et al. Reovirus
Diamond et al. Zika virus has oncolytic activity against glioblastoma stem cells
Burban et al. Exploiting a metabolic vulnerability in brain tumour stem cells using a brain-penetrant drug with safe profile
Zhao TRIM5α is a poxvirus restriction factor: viral evasion strategies and a pathway to antivirals
Holbrook Screening of FDA-Approved Drug Library for Combinatorial Treatment of Pancreatic Ductal Adenocarcinoma Cells with Oncolytic Vesicular Stomatitis Virus
Bongiorno Therapeutic modulation of the tumor-promoting immune type 2 microenvironment in malignant glioma by the induction of a type 1 response to attenuated rabies virus
Sutherland Functions of the viral attachment protein in reovirus neurovirulence
Qin Characterization of mammalian orthoreovirus (MRV) induced stress granules (SGs) and implications of eIF2α phosphorylation on viral translation
Dillard Development and characterization of a recombinant vesicular stomatitis virus (rvsv) for the treatment of glioblastoma

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)